[Form 4] Kindly MD, Inc. Insider Trading Activity
Kindly MD, Inc. (NAKA) reports a grant of 751,879 restricted stock units (RSUs) to reporting person David F. Bailey in a transaction dated 09/22/2025. The RSUs vest over four years with a 12-month cliff measured from August 15, 2025: 25% vests at the end of the cliff and the remaining 75% vests in equal quarterly installments over the following 36 months, subject to continued service. After this grant the reporting person beneficially owns 11,912,451 shares. The RSUs have no purchase price reported and are time-based equity compensation intended to align executive incentives with shareholder outcomes.
- Long-term alignment: RSUs vest over four years with a 12‑month cliff, encouraging retention and focus on multi‑year performance
- No cash outlay required: RSUs have a reported price of $0, indicating time‑based equity rather than an option purchase requirement
- Potential dilution: The award represents 751,879 additional RSUs which could increase share count if vested and settled
- No performance conditions disclosed: Vesting appears solely time‑based, limiting direct pay‑for‑performance linkage in this filing
- Insufficient context on magnitude: The filing does not disclose total shares outstanding or grant value, preventing assessment of proportionality
Insights
TL;DR: A time‑based RSU grant with a one‑year cliff aligns long‑term incentives but creates potential near‑term dilution.
The grant to the CEO/director uses a standard multi‑year vesting structure with a cliff, which reinforces retention and long‑term performance alignment. The filing discloses the exact vesting cadence and that continued service is required for vesting, consistent with customary executive compensation governance. The document does not state whether the award was subject to performance conditions, nor does it disclose board approval details or total shares outstanding for context, limiting assessment of dilution and proportionality.
TL;DR: The RSU package is a sizeable time‑vested award; lack of performance criteria and total share context limits pay‑for‑performance evaluation.
The award of 751,879 RSUs vests 25% after a 12‑month cliff and the remainder quarterly over three years, a conventional retention structure. No exercise price and no performance metrics are disclosed, indicating pure time‑based equity. Without disclosure of grant date fair value, total dilution, or company peer benchmarking, it's not possible to judge whether the grant is market‑competitive or potentially excessive relative to company size.